Qiagen stock: JPMorgan raises target for Qiagen stock to USD 55.00

Published on 10/20/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 535.04 million versus USD 527.50 million. Qiagen stock is EUR 42.48 on October 20, 2026, plus 3.01 percent versus Xetra close.

JPMorgan target raised

JPMorgan raised its Qiagen target to USD 55.00 on October 14, 2026.
Second-quarter revenue reached USD 535.04 million against USD 527.50 million estimates.
Qiagen stock costs EUR 42.48 at Lang & Schwarz on October 20, 2026, 3.01 percent above the Xetra close.
TradingView lists November 10, 2026 as the next earnings date.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0015002SN0) was trading at EUR 42.48 at Lang & Schwarz on October 20, 2026 at 5:10 p.m. CEST, 3.01 percent above the Xetra close of October 19, 2026 at EUR 41.24. The latest analyst move came from JPMorgan, which raised its target from USD 50.00 to USD 55.00 on October 14, 2026, according to MarketBeat.

JPMorgan lifts its target

JPMorgan kept an Overweight rating alongside the higher USD 55.00 target. The target is 29.03 percent above the USD 42.63 equivalent price level implied by the current euro quote and the finance-market currency relationship is not used for a direct valuation comparison here; the analyst target therefore remains a separate USD reference.

MarketBeat reported that Qiagen's second-quarter revenue reached USD 535.04 million, compared with USD 527.50 million expected. That USD 7.54 million difference gives the target story an operating backdrop rather than leaving it as a purely valuation-driven call.

Stock position after 3.01 percent gain

The stock's Xetra price range on October 20, 2026 ran from EUR 41.50 to EUR 41.82, with a close of EUR 41.64 reported for the session. The Lang & Schwarz quote stood above that level later in the day, while the 52-week range in the home-market quote was EUR 27.56 to EUR 47.60. At EUR 42.48, the stock was 10.76 percent below its 52-week high.

Qiagen's market capitalization was EUR 8.7 billion and its price-to-earnings ratio was 24.06 on October 20, 2026. The company generated USD 200.69 million in operating cash flow during the second quarter of 2026, while total assets stood at USD 5.97 billion at June 30, 2026.

Next reporting date is November 10

TradingView lists November 10, 2026 as Qiagen's next earnings date. Qiagen develops sample technologies, molecular testing solutions and bioinformatics products for research and healthcare customers, according to the company's investor-relations overview.

Comparison with peers

Qiagen: plus 3.01 percent, P/E 24.06, market capitalization EUR 8.7 billion.

Danaher Corporation (NYSE, USD): plus 0.36 percent, P/E 40.14, market capitalization USD 158.3 billion.

Thermo Fisher Scientific (NYSE, USD): plus 0.62 percent, P/E 36.77, market capitalization USD 252.8 billion.

Qiagen stock after the target increase

The combination of a higher JPMorgan target and revenue above estimates leaves the next earnings date as the clearest scheduled checkpoint. The October 20 market move also places Qiagen below its yearly high despite the 3.01 percent rise against the October 19 Xetra close.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.